Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,589 questions in 168 reviews · Schizophrenia
current versionsNo studies 601 · 23.2%Ungraded 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
QUETIAPINE vs ARIPIPRAZOLE Mental state: 3. Negative symptoms ‐ average endpoint score (PANSS negative subscore, high = poor) · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 4 studies · 297 participants | Low |
QUETIAPINE vs RISPERIDONE Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 11 studies · 1492 participants | Moderate |
QUETIAPINE vs RISPERIDONE Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 10 studies · 1367 participants | Low |
QUETIAPINE vs RISPERIDONE Quality of life: general average endpoint score QLS total score · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 3 studies · 152 participants | Low |
QUETIAPINE vs RISPERIDONE Adverse effects: 1. Sedation · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 1.21 [1.06, 1.38] | 8 studies · 2226 participants | Ungraded |
QUETIAPINE vs RISPERIDONE Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 0.5 [0.36, 0.69] | 8 studies · 2163 participants | Moderate |
QUETIAPINE vs RISPERIDONE Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 0.96 [0.82, 1.14] | 9 studies · 2070 participants | Moderate |
QUETIAPINE vs ZIPRASIDONE Mental state: 1. General ‐ average endpoint score PANSS total score · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 1 study · 198 participants | Low |
QUETIAPINE vs ZIPRASIDONE Mental state: 2. Positive symptoms ‐ average endpoint score medium term PANSS positive subscore · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 1 study · 198 participants | Low |
QUETIAPINE vs ZIPRASIDONE Mental state: 3. Negative symptoms ‐ average endpoint score medium term PANSS negative subscore · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 1 study · 198 participants | Low |
QUETIAPINE vs ZIPRASIDONE Quality of life: substantial improvement · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
QUETIAPINE vs ARIPIPRAZOLE Quality of life: substantial improvement · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
QUETIAPINE vs ZIPRASIDONE Adverse effects: 1. Sedation · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 1.36 [1.03, 1.81] | 2 studies · 754 participants | Low |
QUETIAPINE vs ZIPRASIDONE Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 0.43 [0.2, 0.93] | 1 study · 522 participants | Low |
QUETIAPINE vs ZIPRASIDONE Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 2.22 [1.35, 3.63] | 2 studies · 754 participants | Moderate |
QUETIAPINE vs ARIPIPRAZOLE Adverse effects: 1. Sedation · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
QUETIAPINE vs ARIPIPRAZOLE Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 0.67 [0.12, 3.57] | 1 study · 40 participants | Low |
QUETIAPINE vs ARIPIPRAZOLE Adverse effects: 3. Metabolic ‐ weight gain ≥7% of total body weight · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | RR 0.52 [0.1, 2.74] | 2 studies · 155 participants | Low |
QUETIAPINE vs CLOZAPINE ‐ all data short term Mental state: 1. General ‐ average endpoint score short term (PANSS total, high = poor) · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 4 studies · 232 participants | Low |
QUETIAPINE vs CLOZAPINE ‐ all data short term Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · participants with schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane | no estimate extracted | 2 studies · 142 participants | Low |
DANCE THERAPY vs STANDARD CARE Service utilisation‐days in hospital · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | no estimate extracted | NR | No studies |
DANCE THERAPY vs STANDARD CARE Clinical global response‐leaving the study early (short term) · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | RR 0.44 [0.04, 4.49] | 1 study · 45 participants | Moderate |
DANCE THERAPY vs STANDARD CARE Clinical global response‐leaving the study early (long term) · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | RR 0.68 [0.31, 1.51] | 1 study · 45 participants | Low |
DANCE THERAPY vs STANDARD CARE Mental state: 2a. Negative symptoms ‐ average score (PANSS negative endpoint, high = poor) · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | no estimate extracted | 1 study · 43 participants | Moderate |
DANCE THERAPY vs STANDARD CARE Mental state: 2b. Negative symptoms ‐ not improved (PANSS negative symptom reduction less than 20‐40%) · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | RR 0.62 [0.39, 0.97] | 1 study · 45 participants | Moderate |
DANCE THERAPY vs STANDARD CARE Satisfaction with care: Average endpoint score (CAT, high = good) · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | no estimate extracted | 1 study · 42 participants | Moderate |
DANCE THERAPY vs STANDARD CARE Quality of life Manchester Short Assessment (MANSA, high = good) · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | no estimate extracted | 1 study · 39 participants | Moderate |
Quetiapine vs Typical antipsychotics Global state No clinical significant response as defined by the individual studies · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | RR 0.96 [0.75, 1.23] | 16 studies · 1607 participants | Moderate |
Quetiapine vs Typical antipsychotics Leaving the study early due to any reason · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | RR 0.91 [0.81, 1.01] | 23 studies · 3576 participants | Moderate |
Quetiapine vs Typical antipsychotics Positive symptoms PANSS positive subscore · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | no estimate extracted | 22 studies · 1934 participants | Moderate |
Quetiapine vs Typical antipsychotics Negative symptoms PANSS negative subscore · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | no estimate extracted | 22 studies · 1934 participants | Moderate |
Quetiapine vs Typical antipsychotics Cognitive function Average endpoint scores as defined by the original studies · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | no estimate extracted | 3 studies · 142 participants | Very low |
Quetiapine vs Typical antipsychotics Extrapyramidal effects · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | RR 0.17 [0.09, 0.32] | 8 studies · 1095 participants | Moderate |
Quetiapine vs Typical antipsychotics Prolactin level Average level in ng/mL · patients with schizophrenia Quetiapine versus typical antipsychotic medications for schizophrenia (2013) · Cochrane | no estimate extracted | 4 studies · 1034 participants | Moderate |
Supported employment vs other vocational approaches Employment ‐ obtained any job during the study (high=better) · patients with adults with severe mental illness Supported employment for adults with severe mental illness (2013) · Cochrane | RR 2.62 [2.18, 3.16] | 7 studies · 951 participants | Very low |
Supported employment vs other vocational approaches Employment ‐ days in competitive employment (primary outcome) ‐ long term · patients with adults with severe mental illness Supported employment for adults with severe mental illness (2013) · Cochrane | no estimate extracted | 1 study · 204 participants | Very low |
Supported employment vs other vocational approaches Employment ‐ days in any form of paid employment ‐ long term · patients with adults with severe mental illness Supported employment for adults with severe mental illness (2013) · Cochrane | no estimate extracted | 2 studies · 510 participants | Very low |
Supported employment vs other vocational approaches Employment ‐ job tenure for competitive employment (weeks) ‐ long term · patients with adults with severe mental illness Supported employment for adults with severe mental illness (2013) · Cochrane | no estimate extracted | 1 study · 204 participants | Very low |
Supported employment vs other vocational approaches Employment ‐ job tenure for any paid employment (weeks) ‐ long term · patients with adults with severe mental illness Supported employment for adults with severe mental illness (2013) · Cochrane | no estimate extracted | 2 studies · 423 participants | Very low |
Supported employment vs other vocational approaches Time (days) to first competitive employment ‐ long term · patients with adults with severe mental illness Supported employment for adults with severe mental illness (2013) · Cochrane | no estimate extracted | 1 study · 204 participants | Very low |
Atypical antipsychotics vs placebo (only short term) Weight gain · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 107 participants | Moderate |
Atypical vs atypical antipsychotics (only short term) No improvement (clozapine vs olanzapine) · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 39 participants | High |
Atypical vs atypical antipsychotics (only short term) Use of other antipsychotics · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 28 participants | Moderate |
Atypical vs atypical antipsychotics (only short term) Drug‐induced diabetes (clozapine vs olanzapine) · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 28 participants | Moderate |
Atypical vs atypical antipsychotics (only short term) Elevated prolactin (risperidone vs quetiapine) · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 22 participants | Moderate |
Atypical vs atypical antipsychotics (only short term) Weight gain in kg (risperidone vs olanzapine) · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 76 participants | High |
Atypical vs atypical antipsychotics (only short term) Leaving the study early because of weight gain (risperidone vs olanzapine) · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 19 participants | Low |
Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term) No response · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 255 participants | High |
Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term) Symptomatic hyperprolactinaemia · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 257 participants | High |
Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term) Use of antiparkinsonian medications · individuals with psychosis Atypical antipsychotics for psychosis in adolescents (2013) · Cochrane | no estimate extracted | 1 study · 257 participants | High |